S-1/A: Kraig Biocraft Laboratories Files Amendment No. 16 to Form S-1 Registration Statement

Kraig Biocraft Laboratories files an amendment to its registration statement to include updated financial information and details about a proposed public offering.

Summary

• Kraig Biocraft Laboratories has filed Amendment No. 16 to its Form S-1 registration statement.
• This amendment includes information from the company's 2023 Annual Report and the Q3 2024 Quarterly Report.
• The company is planning a public offering of 1,904,762 units, each consisting of one share of Class A common stock and one warrant.
• The assumed initial offering price is $5.25 per unit, with an anticipated price range between $4.25 and $6.25.
• The warrants are immediately exercisable and will expire five years from the date of issuance.
• The company has applied to list its common stock and warrants on NASDAQ, but may apply for it be listed on a different national exchange.
• The company intends to use the net proceeds from the offering for expansion of production operations in Vietnam and for working capital and general business purposes.
• The company's financial statements include a going concern qualification due to net losses and a capital deficiency.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has innovative technology and a clear plan for expansion, the going concern qualification, lack of revenue, and dependence on capital raises create significant risks. The sentiment is cautiously optimistic but with a strong awareness of the challenges ahead.

Positives

• The company is actively pursuing a listing on a national exchange.
• The company has a clear plan for the use of proceeds from the offering.
• The company has developed a method for the production of high-performance bio-degradable, bio-compatible, and ecologically friendly recombinant spider silk materials.
• The company's technology is a direct drop-in replacement for traditional silk manufacturing, allowing any silk operation employing our silkworm technology to immediately be converted, without any additional need for capital investment.

Negatives

• The company has a going concern qualification due to net losses and a capital deficiency.
• There is a limited public trading market for the company's common stock.
• The company has a limited operating history and has not yet generated significant revenue.
• The company is dependent on raising capital to continue its business.
• The company's production system is based upon living transgenic organisms, which carries inherent risks.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company may be unable to generate revenues and become profitable.
• The company may not be able to maintain an effective system of internal controls.
• The company may not be able to protect its intellectual property rights.
• The company's production system is based on living transgenic organisms, which carries inherent risks.
• The company's business, operations, and plans could be adversely affected by health epidemics, including COVID-19.
• The company faces competition from larger companies with greater financial resources.
• The company's products could expose it to product liability claims.
• The company's products are based on GMOs, which are subject to public opinion and concerns.
• The company's operations could be affected by natural disasters, pandemics, or other catastrophic events.
• The company may not be able to manage its growth effectively.
• The company may be unable to meet or sustain pricing or material performance requirements.
• The company's ability to uplist to a national exchange is contingent on meeting listing criteria.
• The company's stock price may be volatile and may be affected by market conditions beyond its control.

Future Outlook

The company expects to incur significant research and development costs for the foreseeable future and is focused on expanding production capacity in Vietnam and securing product collaborations.

Management Comments

• Management believes that the new platform technology will allow the company to outpace and surpass Dragon Silk.
• Management views the in-factory microbiology lab as a critical element to successful large-scale production.
• Management continues to stockpile critical inventories and establish alternative supply and vendor chains as a precaution against future pandemics, disasters, or governmental actions.

Industry Context

The company is operating in the specialty fiber and technical textile industries, which are characterized by rapid technological changes and competition. The company is attempting to disrupt the market by adapting existing silk industry infrastructure to produce high-performance silk.

Comparison to Industry Standards

• The company's technology is a direct drop-in replacement for traditional silk manufacturing, which is a unique approach compared to competitors like Bolt Threads and Spiber, who use fermentation processes.
• The company's approach minimizes the need for expansion capital, limiting direct investment and contracting with existing secondary fiber processors, unlike competitors who have raised and spent hundreds of millions of dollars.
• The company's focus on using genetically modified silkworms to produce spider silk is a different approach compared to competitors who use fermentation processes.
• The company's production system is based on a renewable resource and does not use petrochemicals, which is a more environmentally friendly approach than competitors who use petroleum derivatives.

Related Party Transactions

• The company has significant related party transactions, including accrued salaries, officer loans, and royalty payments to its CEO.
• The company has issued warrants to officers and directors as part of their compensation.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial situation.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers may be impacted by delays in product development and commercialization.
• Suppliers may face uncertainty due to the company's financial situation.
• Creditors face the risk of non-payment due to the company's going concern qualification.

Next Steps

• The company plans to expand research and development to create next-generation materials and improve silkworm robustness.
• The company plans to develop a line of fabrics and apparel in collaboration with partners.
• The company plans to continue expanding its spider silk production capacity.
• The company plans to pursue collaborative research and product testing opportunities.
• The company plans to actively pursue commercialization, marketing, and manufacturing opportunities.

Key Dates

Keywords

recombinant spider silk, technical textile, genetically engineered silkworms, public offering, NASDAQ, warrants, going concern, biotechnology, specialty fibers, Dragon Silk, Monster Silk